Stopping Pharma’s Ripoffs and Drug Savings For All Act

# Summary of HR 890: Stopping Pharma's Ripoffs and Drug Savings For All Act **What the bill would do:** This bill tackles a practice called "double patenting," where pharmaceutical companies obtain multiple patents on the same drug. The bill would require drug companies to prove that each patent covers a genuinely different invention; if they can't prove this, all the extra patents would expire when the first patent does. The bill also directs the U.S. Patent and Trademark Office to tighten its review process to prevent granting multiple patents on identical drugs in the first place. **Who it affects:** Primarily pharmaceutical companies and the generic drug industry.

The bill aims to help generic and biosimilar drug makers bring cheaper alternatives to market faster by preventing companies from using multiple patents to extend monopoly control over a drug. Ultimately, patients could benefit through lower drug prices and faster access to more affordable medications. **Current status:** The bill is currently in committee (HR 890, 119th Congress), meaning it hasn't yet advanced for a full vote in the House. It was introduced by Representative Patrick Ryan, a Democrat from New York.